SAINT-GENIS-POUILLY, FRANCE / ACCESSWIRE / March 22, 2017 / Advanced Accelerator Applications S.A. (NASDAQ: AAAP) will host a conference call and live webcast to discuss the results of the year-end 2016, to be held Thursday, March 23, 2017 at 10:00 AM Eastern Time.
Live Event Information
To participate, connect approximately 5 to 10 minutes before the beginning of the event.
- Date, Time: March 23, 2017 at 10:00 AM ET
- Toll Free: 877-407-8133
- International: 201-689-8040
- Live Webcast: www.investorcalendar.com/IC/CEPage.asp?ID=175722 or www.adacap.com
Replay Information
The replay will be available beginning approximately 2 hours after the completion of the live event, ending at midnight Eastern on April 23, 2017.
- Toll Free: 877-481-4010
- International: 919-882-2331
- Replay ID#: 10274
- Webcast: www.investorcalendar.com or www.adacap.com
About Advanced Accelerator Applications
Advanced Accelerator Applications is an innovative radiopharmaceutical company that develops, produces, and commercializes Molecular Nuclear Medicine products. AAA's lead investigational therapeutic candidate, lutetium Lu 177 dotatate (Lutathera®), is a novel MNM compound that AAA is currently developing for the treatment of Neuroendocrine Tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 22 production and R&D facilities able to manufacture both diagnostic and therapeutic MNM products, and has 500 employees in 13 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, the U.S., and Canada). AAA reported sales of €88.6 million in 2015 (+27% vs. 2014) and sales of €81.3 million for the first 9 months of 2016 (+23% vs. 9 months 2015). AAA is listed on the Nasdaq Global Select Market under the ticker "AAAP." For more information, please visit: www.adacap.com.
SOURCE: Investor Network